Last reviewed · How we verify
Biphasic Remogliflozin Etabonate
Biphasic Remogliflozin Etabonate is a sodium-glucose cotransporter 2 (SGLT2) inhibitor.
Biphasic Remogliflozin Etabonate is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Used for Type 2 diabetes.
At a glance
| Generic name | Biphasic Remogliflozin Etabonate |
|---|---|
| Sponsor | BHV Pharma |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
SGLT2 inhibitors work by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine. This results in decreased glucose levels in the blood, which can help lower blood sugar levels in people with diabetes. By inhibiting SGLT2, Biphasic Remogliflozin Etabonate helps to reduce glucose reabsorption and increase glucose excretion.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital mycotic infections
- Increased risk of urinary tract infections
- Increased risk of hypotension
Key clinical trials
- Safety and Efficacy of Biphasic Remogliflozin Etabonate in the Treatment of Type 2 Diabetes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Biphasic Remogliflozin Etabonate CI brief — competitive landscape report
- Biphasic Remogliflozin Etabonate updates RSS · CI watch RSS
- BHV Pharma portfolio CI